… In conclusion, for non-hospitalized patients with COVID-19 who are at high risk of
disease progression, the currently recommended anti-viral agents, nirmatrelvir plus ritonavir, …

… COVID-19 illness, mostly from hospital settings with short follow-up times. This study recruited
non-hospitalized COVID-19 patients … We invited patients with PCR-confirmed COVID-19. A …

… Reducing the variation in the description is paramount in order to establish a common
understanding of the prevalence of specific symptoms after COVID-19 [2]. In our manuscript, we …

Introduction Coronavirus disease 2019 (COVID-19) is prevalent among young people, and
neurological involvement has been reported. We investigated neurological symptoms, …

Background Limited evidence exists on sex differences in post‐COVID fatigue among non‐hospitalized
patients. Therefore, aim of the study was to evaluate the course of chronic …

… Since COVID-19 can cause damage to this system, long-term sequelae might alter control
… This study aimed to evaluate the postural balance of patients with post-acute COVID-19 …

… Despite large diversity of behaviors among anosmic patients in the COVID-19 pandemic,
we can observe a great similarity in the pattern of anosmia in non-hospitalized patients, …

… in COVID-19 patients. The aim of the study therefore is to investigate different types of
oral manifestations in COVID-19 patients as well as their prevalence. Patients and Methods …

… In conclusion, our study supports the use of molnupiravir in non-hospitalized patients with
COVID-19. Further research should be focused on evaluating its comparative efficacy in …

… In this study, we examined a cohort of non-hospitalized patients with post-COVID-19
condition to identify a possible explanation for the exercise intolerance and fatigue, commonly …